As outcry builds over Trump cuts to NIH payments, drugmakers are MIA

Taking stock of the drug industry, from the lab to the medicine chest

February 11, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | As outcry builds over Trump cuts to NIH payments, drugmakers are MIA The biotech and pharma industries, major beneficiaries of academic research, have largely stayed quiet since the Trump administration announcement. By Adam Feuerstein Halt on Trump administration's cuts to NIH research payments expanded nationwide The temporary restraining order was sought by medical, pharmacy, and public health schools, as well as Boston and New York-area hospitals By Jonathan Wosen Opinion: How the 'amyloid mafia' took over Alzheimer's research One group's influence, prestige, networking, and prolific writings help enforce a singular scientific and commercial vision for Alzheimer's. By Charles Piller — Science DANIEL LEAL/AFP via Getty Images STAT+ | How RFK Jr. could revive a dormant task force to scrutinize vaccine safety As health secretary, Kennedy could revive a defunct task force to scrutinize the safety of shots given to babies and kids. By Sarah Owermohle and Rachel Cohrs Zhang

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser